Shares of INNOVENT BIO (01801) surged by 13.69% on November 4, 2024, outperforming the broader Hong Kong market. The pharmaceutical company's stock surge was driven by its announcement of terminating a subscription agreement with Lostrancos and reaffirming its commitment to international business expansion.
The Hong Kong stock market opened with mixed results, with the Hang Seng Index (HSI) rising 0.30% and the Hang Seng Tech Index (HSTECH) surging 1.08%. While the electric vehicle sector showed significant gains, with companies like XPeng, Geely Auto, and BYD climbing, investor sentiment was diverse across different sectors.
INNOVENT BIO's decision to terminate the agreement with Lostrancos was viewed positively by investors, who believe it will allow the company to focus more on its global expansion plans. The company's commitment to international growth appears to have boosted investor confidence, leading to the substantial stock price increase.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。